From Reborn Wikipedia

The blue pill was marketed by Pfizer as DE-agent and recently studies as preventive of premature ejaculation [1] Graciano et al (2017) present a mechanism for hepatotoxicity of this medicine, also many counterfeit plant preparations, involving CYP3A4 enzymes [2] Further questions remains[3] Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents[4]


comparable efficacy shows tadalafil

Cialis 7 28 29.jpg
  • Preeclampsia

a recent study excluded tadalafil [7]


Treatment with oral sildenafil 40 mg t.i.d. for 6 months in patients with persistent PH after successful correction of VHD is associated to unfavourable clinical outcomes as compared to placebo[8]


McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25. PMID: 26113687.

Immune system[edit]

..can affect innate and adaptative immune systems


  1. Krishnappa P, Fernandez-Pascual E, Carballido J, Martinez-Salamanca JI. Sildenafil/Viagra in the treatment of premature ejaculation. Int J Impot Res. 2019 Mar;31(2):65-70. doi: 10.1038/s41443-018-0099-2. Epub 2019 Mar 5. PMID: 30837718.
  3. ...time to looks beyond Pulmonary Pressures
  4. Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther. 2019 Jul/Aug;26(4): e520-e526. doi: 10.1097/MJT.0000000000000766. PMID: 30946047
  5. Int Urol Nephrol (2017) 49:1731–1740 direct comparison of tadalafil...
  6. In chinese
  8. Bermejo, J., Yotti, R., García-Orta, R., Sánchez-Fernández, P. L., Castaño, M., Segovia-Cubero, J., Escribano-Subías, P., San Román, J. A., Borrás, X., Alonso-Gómez, A., Botas, J., Crespo-Leiro, M. G., Velasco, S., Bayés-Genís, A., López, A., Muñoz-Aguilera, R., de Teresa, E., González-Juanatey, J. R., Evangelista, A., Mombiela, T., … Sildenafil for Improving Outcomes after Valvular Correction (SIOVAC) investigators (2018). Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. European heart journal, 39(15), 1255–1264.